Mather Group, Llc. Supernus Pharmaceuticals, Inc. Transaction History
Mather Group, Llc.
- $7.74 Billion
- Q3 2024
A detailed history of Mather Group, Llc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Mather Group, Llc. holds 110 shares of SUPN stock, worth $3,912. This represents 0.0% of its overall portfolio holdings.
Number of Shares
110
Previous 250
56.0%
Holding current value
$3,912
Previous $6,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
282Shares Held
61.1MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$370 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$218 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$181 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$103 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$93.6 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.9B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...